A Novel Orally Active HDAC6 Inhibitor T-518 Shows a Therapeutic Potential for Alzheimer’s Disease and Tauopathy in Mice

Researchers characterized N-[(1R,2R)-2-{3-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-5-oxo-5H,6H,7H-pyrrolo[3,4-b]pyridin-6-yl}cyclohexyl]-2,2,3,3,3-pentafluoropropanamide (T-518), a novel, potent, highly selective histone deacetylase 6 inhibitor with clinically favorable pharmacodynamics.